Tag: global blood therapeutics

January 30, 2019

GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) today announced that data from its Phase 1/2 study of voxelotor in patients with sickle cell...
December 7, 2018

Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering

Global Blood Therapeutics (Nasdaq:GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to...
December 3, 2018

GBT Announces Positive 24-week Results from Phase 3 HOPE Study

Global Blood Therapeutics (Nasdaq:GBT) today announced updated efficacy and safety results from Part A of its Phase 3 HOPE Study...
August 23, 2018

GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis

Global Blood Therapeutics (NASDAQ:GBT) announced today that it has entered into an exclusive worldwide licensing agreement with F. Hoffmann-La Roche...
June 27, 2018

GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) announced the completion of a planned review of Part A of the Phase 3 HOPE (Hemoglobin Oxygen...